NICOTINE LACTATE

Details

Stereochemistry	EPIMERIC
Molecular Formula	C10H14N2.C3H6O3
Molecular Weight	252.3095
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)C(O)=O.CN1CCC[C@H]1C2=CN=CC=C2

InChI

InChIKey=VWTHFJXLFGINSW-PPHPATTJSA-N

InChI=1S/C10H14N2.C3H6O3/c1-12-7-3-5-10(12)9-4-2-6-11-8-9;1-2(4)3(5)6/h2,4,6,8,10H,3,5,7H2,1H3;2,4H,1H3,(H,5,6)/t10-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C3H6O3
Molecular Weight	90.0779
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	C10H14N2
Molecular Weight	162.2316
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: www.inchem.org/documents/pims/chemical/nicotine.htm
Curator's Comment: description was created based on several sources, including https://cancercontrol.cancer.gov/brp/tcrb/monographs/1/index.html https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928221/

Nicotine is a natural alkaloid obtained from the dried leaves and stems of the nightshade family of pants, such as Nicotiana tabacum and Nicotiana rustica, where it occurs in concentrations of 0.5-8%. Cigarette tobacco varies in its nicotine content, but common blends contain 15-25 mg per cigarette, with a current trend towards lower levels. Nicotine is highly addictive substance, it exhibits a stimulant effect when adsorbed at 2 mg. Administration of higher doses could be harmful. Action of nicotine is mediated by nicotinic cholinergic receptors. Nicotine binds to the interface between two subunits of the receptors, opens the channel and allows the entry of sodium or calcium. The principal mediator of nicotine dependence is α4β2 nicotine receptor.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Neuronal acetylcholine receptor; alpha4/beta2 77 Target ID: CHEMBL1907589 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15528443	Agonist 2752	7.9 null [pKi]
Neuronal acetylcholine receptor; alpha3/beta4 40 Target ID: CHEMBL1907594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22148173	Agonist 2752	260.0 nM [Ki]
Neuronal acetylcholine receptor protein alpha-7 subunit 78 Target ID: CHEMBL2492 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15528443	Agonist 2752	3.0 µM [Ki]
Neuronal acetylcholine receptor; alpha9/alpha10 7 Target ID: CHEMBL2109238 Sources: http://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=76	Antagonist 2849
Nicotinic acetylcholine receptors 17 Target ID: Nicotinic acetylcholine receptors Sources: http://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=76	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Nicotine dependence 33 Sources: https://www.drugs.com/pro/equaline-nicotine-lozenge.html	Palliative		Approved 8583	NICORETTE Approved Use Reduces withdrawal symptoms, including nicotine craving associated with quitting smoking Launch Date 1984

C_max

Value	Dose	Co-administered	Analyte	Population
12 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020385s011lbl.pdf	1 mg single, nasal dose: 1 mg route of administration: Nasal experiment type: SINGLE co-administered:		NICOTINE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
6 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020385s011lbl.pdf	1 mg single, nasal dose: 1 mg route of administration: Nasal experiment type: SINGLE co-administered:		NICOTINE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
3 min DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020385s011lbl.pdf	1 mg single, nasal dose: 1 mg route of administration: Nasal experiment type: SINGLE co-administered:		NICOTINE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
95% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020385s011lbl.pdf	1 mg single, nasal dose: 1 mg route of administration: Nasal experiment type: SINGLE co-administered:		NICOTINE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT1 620 OCT2 779 OCT3 159 OCTN1 32 OCTN2 71	CYP2A6 626 UGT2B10 131 UGT2B17 237 UGT1A4 399 FMO3 77 CYP2A13 12 CYP2B6 776 OCT2 434 UGT1A9 423 MATE1 182	CYP1A2 832 CYP2E1 131

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inducer 1966 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243019/ Page: -	no
CYP2E1 1146	inducer 1966 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2125.2009.03568.x Page: -	yes
OCT1 656	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0197018612003877 Page: -	yes
OCT2 782	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0197018612003877 Page: -	yes
OCT3 161	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0197018612003877 Page: -	yes
OCTN1 32	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0197018612003877 Page: -	yes
OCTN2 71	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0197018612003877 Page: -	yes

Drug as victim

Target	Modality	Activity
CYP2A13 12	substrate 4014 Sources: https://link.springer.com/chapter/10.1007/978-3-540-69248-5_2 Page: 245.0	minor
CYP2B6 776	substrate 4014 Sources: https://link.springer.com/chapter/10.1007/978-3-540-69248-5_2 Page: 245.0	minor
UGT1A9 423	substrate 4014 Sources: https://molpharm.aspetjournals.org/content/72/3/761 Page: -	no
CYP2A6 626	substrate 4014 Sources: https://ascpt.onlinelibrary.wiley.com/doi/full/10.1016/j.clpt.2004.02.011 Page: -	yes
FMO3 77	substrate 4014 Sources: https://link.springer.com/chapter/10.1007/978-3-540-69248-5_2 Page: 245.0	yes
MATE1 182	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0197018612003877 Page: -	yes
OCT2 434	substrate 4014 Sources: https://link.springer.com/chapter/10.1007/978-3-540-69248-5_2 Page: 60.0	yes
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17909004/ Page: -	yes
UGT2B10 131	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/20876810/ Page: -	yes
UGT2B17 237	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/20876810/ Page: -	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://journals.physiology.org/doi/full/10.1152/ajpheart.1999.277.3.H1081 Page: -

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-1634	http://www.3bsc.com/index/pro_info.php?id=55353
AA Blocks	AA018PRG	https://www.aablocks.com/goods/Goods/detail?id=AA018PRG
abcr GmbH	AB118155	http://www.abcr.com/shop/en/AB118155
AbMole Bioscience	M5749	http://www.abmole.com/products/l-nicotine.html
Achemtek	0102-025835	http://www.achemtek.com/54-11-5
Acorn PharmaTech	ACN-047159	http://www.acornpharmatech.com/
Acros Organics	AC181420050	https://www.fishersci.com/shop/products/l-nicotine-99-acros-organics/AC181420050
Acros Organics	AC181420250	https://www.fishersci.com/shop/products/l-nicotine-99-acros-organics/AC181420250
Acros Organics	AC181421000	https://www.fishersci.com/shop/products/l-nicotine-99-acros-organics/AC181421000
Acros Organics	AC181425000	https://www.fishersci.com/shop/products/l-nicotine-99-acros-organics-3/AC181425000
AHH Chemical co.,ltd	MT-00062	http://www.ahhchemical.com/product/MT-00062.html
AHH Chemical co.,ltd	NP-1207	http://www.ahhchemical.com/product/NP-1207.html
Alfa Aesar	A12398	https://www.alfa.com/en/catalog/A12398/
Alfa Chemistry	284685-07-0	https://www.alfa-chemistry.com/cas_284685-07-0.htm
Alfa Chemistry	ACM54115	https://www.alfa-chemistry.com/nicotine-cas-54-11-5-item-1430.htm
Angene	AGN-PC-0JKDO3	http://www.angenechemical.com/productshow/AGN-PC-0JKDO3.html
Angene	AGN-PC-0O89FM	http://www.angenechemical.com/productshow/AGN-PC-0O89FM.html
ApexBio Technology	A8482	http://www.apexbt.com/nicotine-difartrate.html
Aurora Fine Chemicals LLC	A13.139.618	http://online.aurorafinechemicals.com/info?ID=A13.139.618
Avantor Inc	200006-856	https://us.vwr.com/store/product/7516631/s-nicotine
Avantor Inc	200006-858	https://us.vwr.com/store/product/7516631/s-nicotine
Avantor Inc	75835-322	https://us.vwr.com/store/product/21998648/exempted-drug-of-abuse-reference-standards-restek
Avantor Inc	BT130705-100G	https://us.vwr.com/store/product/16900436/s-nicotine-99
Avantor Inc	BT130705-25G	https://us.vwr.com/store/product/16900436/s-nicotine-99
BioSynth	J-500021	https://www.biosynth.com/en/products/all-products/products/J-500021.html
BLD Pharm	BD01315752	http://www.bldpharm.com/products/104062-50-2.html
Chem Scene	CS-3999	http://www.chemscene.com/54-11-5.html
ChemFaces	CFN99512	http://www.chemfaces.com/natural/L-Nicotine-CFN99512.html
ChemMol	97600113	http://www.chemmol.com/chemmol/97600113.html
ChemMol	99102363	http://www.chemmol.com/chemmol/99102363.html
Chemspace	CSSS00015193816	https://chem-space.com/CSSS00015193816
DC Chemicals	DCY-181	http://www.dcchemicals.com//product_show-L_Nicotine.html
Enamine	Z1954805269	https://www.enaminestore.com/catalog/Z1954805269
eNovation Chemicals	D659532	https://www.enovationchem.com/ProductDetails.asp?ProductID=D659532
Glentham Life Sciences	GK9991	http://www.glentham.com/products/product/GK9991/
Hairui	HR132183	http://www.hairuichem.com/en/product/25013-16-5.html
LGC Standards	DRE-A15520000ME-1000	https://www.lgcstandards.com/US/en/p/DRE-A15520000ME-1000
LGC Standards	DRE-CA15520000	https://www.lgcstandards.com/US/en/p/DRE-CA15520000
LGC Standards	DRE-CR15520000	https://www.lgcstandards.com/US/en/p/DRE-CR15520000
LGC Standards	DRE-L15520000ME	https://www.lgcstandards.com/US/en/p/DRE-L15520000ME
LGC Standards	DRE-XA15520000ME	https://www.lgcstandards.com/US/en/p/DRE-XA15520000ME
Matrix Scientific	153938	https://www.matrixscientific.com/153938.html
mcule	MCULE-8728421654	https://mcule.com/MCULE-8728421654/
MedChem Express	HY-B0638	http://www.medchemexpress.com/L-Nicotine.html
MuseChem	I000016	https://www.musechem.com/product/I000016.html
MuseChem	M122880	https://www.musechem.com/product/M122880.html
Oakwood	241305	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=122304&ExtHyperLink=1
OChem	4370	http://www.ocheminc.com/index.php?act=psearch&pid=006N369
Sigma-Aldrich	36733_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/36733?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	46343_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/46343?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	N-008_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/n008?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	N3876_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/n3876?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	N5511_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/n5511?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S537179	http://www.smolecule.com/products/s537179
Smolecule	S750181	https://www.smolecule.com/products/s750181
Synblock Inc	SB12751	http://www.synblock.com/product/54-11-5.html
TCI (Tokyo Chemical Industry)	N0079	http://www.tcichemicals.com/eshop/en/us/commodity/N0079/index.html
THE BioTek	bt-277084	https://www.thebiotek.com/product/inhibitors/bt-277084
VladaChem	VL143555	https://www.vladachem.com/product.php?products=54-11-5
Yuhao Chemical	LQ0003	http://www.chemyuhao.com/54-11-5.html

PubMed

Title	Date	PubMed
Modulation of phosphatidylinositol turnover on central nicotinic receptors.	1997 Jul	10072918
Nicotine potentiates sulpiride-induced catalepsy in mice.	1998	10958255
[Treatment outcome in tobacco dependence after nicotine replacement therapy and group therapy].	1999	10497441
Inducible, heterologous expression of human alpha7-nicotinic acetylcholine receptors in a native nicotinic receptor-null human clonal line.	1999 Apr 17	10216184
Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant.	1999 Feb 5	10082212
Transdermal nicotine mimics the smoking-induced endothelial dysfunction.	2000 Aug	10976548
Genetic and pharmacological strategies identify a behavioral function of neuronal nicotinic receptors.	2000 Aug	10942032
Chick optic lobe contains a developmentally regulated alpha2alpha5beta2 nicotinic receptor subtype.	2000 Aug	10908297
Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment.	2000 Jun 15	10799646
[A comparative study of the central H-cholinergic-blocking and NMDA-blocking actions of MK-801, memantin, amantadine, pyrilen and IEM-1754 in experiments on intact rats].	2000 Mar-Apr	10834088
Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine.	2000 Sep	10945867
Nicotine is a potent blocker of the cardiac A-type K(+) channels. Effects on cloned Kv4.3 channels and native transient outward current.	2000 Sep 5	10973847
Chronic nicotine exposure reduces N-methyl-D-aspartate receptor-mediated damage in the hippocampus without altering calcium accumulation or extrusion: evidence of calbindin-D28K overexpression.	2001	11226671
Nicotine inhibits UV-induced activation of the apoptotic pathway.	2001 Dec 15	11701223
Nicotine self-administration and withdrawal: modulation of anxiety in the social interaction test in rats.	2001 Jan	11271403
Cardiovascular effects of transdermal nicotine in mildly hypertensive smokers.	2001 Jul	11465642
Nicotine produces selective degeneration in the medial habenula and fasciculus retroflexus.	2001 Jul 6	11430869
Nicotine metabolism and CYP2A6 allele frequencies in Koreans.	2001 Jun	11434509
Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method.	2001 Nov 30	11684323
Nicotine affects the signaling of the death pathway, reducing the response of head and neck cancer cell lines to DNA damaging agents.	2001 Oct	11592233
Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine.	2001 Sep	11605085
Efficient enantiomeric synthesis of pyrrolidine and piperidine alkaloids from tobacco.	2001 Sep 21	11559179
Molecular orbital calculations and nicotine metabolism: a rationale for experimentally observed metabolite ratios.	2002	12222752
Induction of CYP1A1 and CYP1A2 expressions by prototypic and atypical inducers in the human lung.	2002 Apr 8	11849738
Alcohol and nicotine reduce cell proliferation and enhance apoptosis in dentate gyrus.	2002 Aug 27	12218695
Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior.	2002 Feb	11805739
Increased sensitivity to nicotine-induced seizures in mice heterozygous for the L250T mutation in the alpha7 nicotinic acetylcholine receptor.	2002 Feb 11	11893908
Absence of alpha7-containing neuronal nicotinic acetylcholine receptors does not prevent nicotine-induced seizures.	2002 Jan 31	11834293
Enhancement of cocaine-seeking behavior by repeated nicotine exposure in rats.	2002 Jul	12110995
The selectively bred high alcohol sensitivity (HAS) and low alcohol sensitivity (LAS) rats differ in sensitivity to nicotine.	2002 Jun	12068243
N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonist: inhibition of S(-)-nicotine-evoked [(3)H]dopamine overflow from superfused rat striatal slices.	2002 Jun	12023541
Increased sensitivity to nicotine-induced seizures in mice expressing the L250T alpha 7 nicotinic acetylcholine receptor mutation.	2002 Mar	11854451
Effects of whole deletion of CYP2A6 on nicotine metabolism in humans.	2002 May	12024803
Nicotine potentiation of morphine-induced catalepsy in mice.	2002 May	11900788
Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.	2002 Nov	12445030
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.	2003 Jan 1	12464242
Nicotinic acetylcholine receptors and the regulation of neuronal signalling.	2004 Jun	15165747
Nicotine addiction.	2010 Jun 17	20554984
How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self-experiments in the nineteenth century.	2014 Jan	24091634

Patents

Sample Use Guides

In Vivo Use Guide

Reduces withdrawal symptoms, including nicotine craving associated with quitting smoking, nicotine is available as a chewing gum, and is administered according to a schedule at doses 2-4 mg once every 2-4 hours. Nicotine is also available as a transdermal patch.

Route of Administration: Other

In Vitro Use Guide

Functional activity of nicotine against hα4β2 nicotinic receptors was evaluated using the 86Rb+ ion flux assay in SH-EP1 cells, expressing hα4β2. The 86Rb+ efflux was measured using the “flip-plate” technique. Nicotine activated 86Rb+ efflux with EC50 of 290 nM.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 11:21:42 GMT 2025` Edited by `admin` on `Wed Apr 02 11:21:42 GMT 2025`
Record UNII	8XAS3GPB3T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LACTIC ACID, COMPD. WITH NICOTINE

Preferred Name

English

NICOTINE LACTATE

Common Name

English

PROPANOIC ACID, 2-HYDROXY-, COMPD. WITH 3-((2S)-1-METHYL-2-PYRROLIDINYL)PYRIDINE (1:1)

Common Name

English

LACTIC ACID, COMPOUND WITH (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE(1:1)

Systematic Name

English

Code System Code Type Description

CAS

15197-02-1